首頁
瀏覽量: 356
- 產(chǎn)品名稱： Research Grade Rituximab( 利妥昔單抗 )
- 產(chǎn)品貨號： CSD00089
- 貨期： 現(xiàn)貨
- 價格與訂購： 2480
- 數(shù)量：
庫存： 10
- 規(guī)格： 100μg
- 產(chǎn)品信息
- 如何訂購
貨號（Catalog No.）
CSD00089
通用名INN
Rituximab
純度(Purity)
>95%
濃度( Concentration)
1mg/ml
Formulation
PBS buffer PH7.5
Source
CHO cells
內(nèi)毒素(Endotoxin level)
Please contact with the lab for this information.
產(chǎn)品描述(Description)
Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences 6, Label. It was originally approved by the U.S. FDA in 1997 as a single agent to treat patients with B-cell Non-Hodgkin's Lymphoma (NHL) 8, however, has now been approved for a variety of conditions Label. On November 28, 2018, the US FDA approved Truxima, the first biosimilar to Rituxan (Rituximab) 7.Rituximab is a monoclonal antibody that targets the CD20 antigen, which is expressed on the surface of pre-B and mature B-lymphocytes 1, 2, 3, Label. After binding to CD20, rituximab mediates B-cell lysis (or breakdown). The possible mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent cell-mediated cytotoxicity (ADCC) Label.
別名(Alternative names)
IDEC-C2B8
靶點;物種(Specificity target name;species)
MS4A1[Homo sapiens]
活性研究（體外/體內(nèi)研究）(Activity in vitro)
Complement-dependent cytotoxicity(CDC), complement-dependent cellular cytotoxicity(CDCC), antibody-dependent cytotoxicity (ADCC) as well as the induction of apoptosis have been claimed to be responsible for the efficacy of rituximab. Rituximab can induce death of malignant B cell lines in vitro. The strength of this effect varies considerably between target cell lines. Changes that have been identified in response to rituximab in vitro include inhibition of p38 mitogen-activated protein kinase, NF-κB, extracellular signal-regulated kinase 1/2 (ERK 1/2) and AKT antiapoptotic survival pathways. Rituximab is highly efficient at mediating CMC(complement dependent cytotoxicity) of various B cell lines as well as fresh malignant B cell samples. CD20-binding capacity of rituximab is dose-dependent.
種類(Species)
Chimeric
受體鑒定(Receptor identification)
IgG1-kappa
分子量(MV)
148000.00 Da
CAS
174722-31-7
存儲條件(Storage)
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Store at +4°C short term (1-2 weeks).
Store at -20 °C 12 months.
Store at -80°C long term.
Note
For research use only .
地 址：
產(chǎn)品銷售：
E - mail ：
郵 編：
Amily
